Literature DB >> 22068858

Danish type gelsolin-related amyloidosis in a Brazilian family: case reports.

Helena Parente Solari1, Marcelo Palis Ventura, Emilia Antecka, Rubens Belfort Junior, Miguel Noel Burnier.   

Abstract

Familial amyloidosis of the Finnish type (FAF) is an autosomal dominant form of systemic amyloidosis showing marked geographic clustering in Finland. The disease is caused by a point mutation, 654G-A, in the gelsolin gene. The Danish-subtype of FAF has been previously described in three families, the patients present clinical findings similar to FAF, and the mutation 654G-T in the gelsolin gene. Three members from two generations of the same family, with familial amyloidosis, were screened for mutations in the GSN gene. Genomic DNA was extracted from peripheral blood lymphocytes and the polymerase chain reaction (PCR) was carried out under standard conditions, using appropriate primers. Sequence analysis showed the presence of a G to T transition at nucleotide 654 of the gelsolin gene. This is the first report of gelsolin-related familial amyloidosis in a Brazilian family, and the result is particularly significant as this pedigree presents an unusual mutation, described previously in three families, with no known Finnish ancestors (Danish type).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068858     DOI: 10.1590/s0004-27492011000400012

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  8 in total

1.  Clinical features and haplotype analysis of newly identified Japanese patients with gelsolin-related familial amyloidosis of Finnish type.

Authors:  Makiko Taira; Hiroyuki Ishiura; Jun Mitsui; Yuji Takahashi; Toshihiro Hayashi; Jun Shimizu; Takashi Matsukawa; Naoko Saito; Kazumasa Okada; Sadatoshi Tsuji; Hiromasa Sawamura; Shiro Amano; Jun Goto; Shoji Tsuji
Journal:  Neurogenetics       Date:  2012-05-24       Impact factor: 2.660

2.  The First Korean Family With Hereditary Gelsolin Amyloidosis Caused by p.D214Y Mutation in the GSN Gene.

Authors:  Kyoung Jin Park; Jong Ho Park; June Hee Park; Eun Bin Cho; Byoung Joon Kim; Jong Won Kim
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

3.  The First Argentinian Family with Familial Amyloidosis of the Finnish Type.

Authors:  Francisco Lucero Saá; Federico Andrés Cremona; Natalia Ximena Mínguez; María Laura Igarzabal; Pablo Chiaradía
Journal:  Case Rep Ophthalmol       Date:  2017-08-31

4.  The role of gelsolin domain 3 in familial amyloidosis (Finnish type).

Authors:  Habiba Zorgati; Mårten Larsson; Weitong Ren; Adelene Y L Sim; Jan Gettemans; Jonathan M Grimes; Wenfei Li; Robert C Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-26       Impact factor: 11.205

5.  Clinical, histopathological, and in silico pathogenicity analyses in a pedigree with familial amyloidosis of the Finnish type (Meretoja syndrome) caused by a novel gelsolin mutation.

Authors:  Jesus Cabral-Macias; Leopoldo A Garcia-Montaño; Mario Pérezpeña-Díazconti; Marisa-Cruz Aguilar; Guillermo Garcia; Carlos I Vencedor-Meraz; Enrique O Graue-Hernandez; Oscar F Chacón-Camacho; Juan C Zenteno
Journal:  Mol Vis       Date:  2020-05-02       Impact factor: 2.367

6.  Clinical Features and Brain MRI Findings in Korean Patients with AGel Amyloidosis.

Authors:  E Nae Cheong; Wooyul Paik; Young Chul Choi; Young Min Lim; Hyunjin Kim; Woo Hyun Shim; Hyung Jun Park
Journal:  Yonsei Med J       Date:  2021-05       Impact factor: 2.759

7.  Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study.

Authors:  Eeva-Kaisa Schmidt; Tuuli Mustonen; Sari Kiuru-Enari; Tero T Kivelä; Sari Atula
Journal:  Orphanet J Rare Dis       Date:  2020-01-17       Impact factor: 4.123

8.  Analyses Mutations in GSN, CST3, TTR, and ITM2B Genes in Chinese Patients With Alzheimer's Disease.

Authors:  Yaling Jiang; Bin Jiao; Xinxin Liao; Xuewen Xiao; Xixi Liu; Lu Shen
Journal:  Front Aging Neurosci       Date:  2020-09-10       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.